Roche Launches Cobas Eplex RP3 In CE Markets, Featuring First Flexible Syndromic Testing With Up To 5 Customisable Panels For Local Needs
- The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample.
- Rapid results enable doctors to make fast, confident and critical treatment decisions that are vital for high-risk patients.
- Designed for the cobas eplex system, the test is easy to use and available around the clock, helping hospitals manage surges in respiratory cases.
Login to comment